$IMNN earnings report

Imunon reports Q3 2026 net loss available to common shareholders of $3.8 million, or $0.64 per share, versus $1.16 per share a year earlier, and cash of $4.0 million at September 30, 2026. AlphAI read Imunon's Q3 FY2026 filing as weak. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readIMNN · Q3 2026 · ended 2026-09-30

Imunon reports Q3 2026 net loss available to common shareholders of $3.8 million, or $0.64 per share, versus $1.16 per share a year earlier, and cash of $4.0 million at September 30, 2026

↓Weak quarter

The filing shows no revenue and no guidance. Operating expenses were roughly flat, but per-share loss narrowed only because of a much larger share count, total stockholders' equity fell from $7.062 million to $2.622 million, and unrestricted cash of $4.039 million sits against a company that reports a nine-month net cash use of $10.2 million.

EPS · GAAP
$(0.64)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total operating expenses (Q3 2026, three months ended Sep 30)GAAP$3.45M––
Research and development expenses (Q3 2026)GAAP$1.79M––
General and administrative expenses (Q3 2026)GAAP$1.66M––
Loss from operations (Q3 2026)GAAP−$3.45M––
Other (expense) income (Q3 2026)GAAP−$302K––
Net loss (Q3 2026)GAAP−$3.75M––
Deemed dividend on preferred stock (Q3 2026)GAAP−$63K––
Net loss available to common shareholders (Q3 2026)GAAP−$3.81M––
Net loss available to common shareholders per share, basic and diluted (Q3 2026)GAAP$(0.64)––
Research and development expenses (nine months ended Sep 30, 2026)GAAP$5.59M––
General and administrative expenses (nine months ended Sep 30, 2026)GAAP$4.95M––
Total operating expenses (nine months ended Sep 30, 2026)GAAP$10.55M––
Loss from operations (nine months ended Sep 30, 2026)GAAP−$10.55M––
Other (expense) income (nine months ended Sep 30, 2026)GAAP−$267K––
Net loss (nine months ended Sep 30, 2026)GAAP−$10.81M––
Deemed dividend on preferred stock (nine months ended Sep 30, 2026)GAAP−$82K––
Net loss available to common shareholders (nine months ended Sep 30, 2026)GAAP−$10.89M––
Net loss available to common shareholders per share, basic and diluted (nine months ended Sep 30, 2026)GAAP$(2.01)––
Net cash used in operating activities (nine months ended Sep 30, 2026)GAAP$10.2M––
Cash and cash equivalents (Sep 30, 2026, versus Dec 31, 2025)GAAP$4.04M––
Restricted cash (Sep 30, 2026)GAAP$5.04M––
Total assets (Sep 30, 2026, versus Dec 31, 2025)GAAP$12.01M––
Total liabilities (Sep 30, 2026, versus Dec 31, 2025)GAAP$9.39M––
Total stockholders' equity (Sep 30, 2026, versus Dec 31, 2025)GAAP$2.62M––

Capital returns

  • No share repurchases or dividends on common stock are reported in the filing.
  • On September 29, 2026, the Company entered into an Exchange Agreement under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of newly designated, non-convertible Series B Preferred Stock. The Company states the transaction reduces the outstanding balance of the A-1 Note by approximately 43%, increases stockholders' equity and involves no issuance of common stock or warrants.
  • The income statement shows a deemed dividend on preferred stock of $(63) thousand in Q3 2026 and $(82) thousand for the nine months ended September 30, 2026.

What drove it

  • The Company states that Q3 2026 clinical costs for the OVATION studies were $0.4 million, compared with $0.5 million a year earlier, and that as enrollment in OVATION 3 advanced these costs were offset by lower manufacturing and clinical supply costs and lower other clinical and regulatory costs.
  • The Company states that Q3 2026 general and administrative expenses increased to $1.7 million from $1.6 million, primarily reflecting higher outside professional fees.
  • The Company states that nine-month R&D rose to $5.6 million from $5.3 million, with manufacturing and clinical supply costs for the OVATION and MRD programs increasing to $3.3 million from $3.0 million, partially offset by lower costs associated with the MRD Study and the closeout of the OVATION 2 Study.
  • Other (expense) income moved to $(302) thousand in Q3 2026 from $47 thousand in Q3 2025. The filing prints the line but does not explain the change.
  • On October 21, 2026, the Company agreed to sell its rights to ThermoDox to VoxelDox Therapeutics, Inc. In exchange the Company would receive an equity stake, payments of up to $16.5 million contingent on development milestones, and royalties on future net sales after approval. Closing is contingent on VoxelDox raising $2.5 million in funding.
  • On September 10, 2026, the Company entered into a CRADA with the National Cancer Institute, under which NCI's CTEP will assume regulatory sponsorship of IMNN-001 development.

Concerns

  • The Company reported cash and cash equivalents of $4,039 thousand at September 30, 2026, against a nine-month net cash use from operations of $10.2 million. The filing does not describe how the Company will fund operations beyond the cash it reports.
  • Total stockholders' equity declined from $7,062 thousand at December 31, 2025 to $2,622 thousand at September 30, 2026, while total liabilities rose from $5,226 thousand to $9,386 thousand.
  • The Company filed a Form S-1 on October 27, 2026 for a proposed securities offering. The registration statement has not yet become effective.
  • The ThermoDox sale depends on VoxelDox raising $2.5 million, so the proceeds and the $16.5 million in potential milestone payments are contingent.
  • The weighted average share count rose sharply versus the prior year period, which lowered the loss per share even though the net loss increased. Per-share figures are not comparable with the prior year without the share count context.
  • The forward-looking statements section warns that interim clinical results are not necessarily indicative of final results.

What to watch

  • Whether the S-1 offering becomes effective and the size and terms of any financing relative to the $4.0 million of unrestricted cash and the $5.0 million of restricted cash.
  • Whether VoxelDox completes the $2.5 million raise that is a condition of the ThermoDox sale.
  • Enrollment progress in OVATION 3, which the Company expects to complete by the first quarter of 2029, and the two planned interim analyses.
  • Trend in G&A, which the Company attributes to higher outside professional fees, and in manufacturing and clinical supply costs for the OVATION and MRD programs.
  • Further results from the IMNN-001 Phase 2 OVATION 2 data and the Phase 2 MRD study, including the translational data presented at SITC 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $4.0 million at September 30, 2026 (printed as $4,039 thousand), compared with $8,781 thousand at December 31, 2025.
  • The Company held an additional $5.0 million of restricted cash at September 30, 2026 (printed as $5,039 thousand), shown under other assets. The balance sheet shows no restricted cash at December 31, 2025.
  • Net cash used in operating activities was $10.2 million for the nine months ended September 30, 2026, which the filing describes as unchanged from the same period last year. The prior-year figure is not printed in the text.
  • Note payable current portion (Note A) was $1,380 thousand and Note Payable (Note B) noncurrent was $4,884 thousand at September 30, 2026. The balance sheet shows no notes payable at December 31, 2025.
  • Accounts payable and accrued liabilities fell from $4,217 thousand at December 31, 2025 to $2,414 thousand at September 30, 2026.
  • Preferred stock, including additional paid-in capital, was $3,384 thousand at September 30, 2026, against nil at December 31, 2025.
  • Accumulated deficit rose from $(421,298) thousand to $(432,111) thousand.

Analysis

Imunon's Q3 2026 release contains no revenue line and no guidance. The results are an operating loss and a net loss. Total operating expenses were $3,448 thousand in Q3 2026 against $3,476 thousand a year earlier, and R&D fell to $1,793 thousand from $1,899 thousand while G&A rose to $1,655 thousand from $1,577 thousand. The Company attributes the G&A increase primarily to higher outside professional fees. Net loss was $(3,750) thousand, and net loss available to common shareholders was $(3,813) thousand after a $(63) thousand deemed dividend on preferred stock. The reported loss per share was $(0.64), compared with $(1.16) a year earlier. The nine-month figures show a similar pattern: total operating expenses of $10,546 thousand against $10,389 thousand, and a net loss available to common shareholders of $(10,895) thousand against $(10,272) thousand. Nine-month loss per share was $(2.01) against $(5.53).

The per-share comparison needs care. The weighted average share count in the statement of operations rose from 2,944 thousand in Q3 2025 to 5,947 thousand in Q3 2026, and from 1,856 thousand to 5,408 thousand over the nine months. The filing does not explain this change in its text. The narrower loss per share therefore reflects a larger share count on a net loss that increased, and the two per-share figures should not be read as an improvement in underlying loss.

The balance sheet shows the financing pressure more clearly than the income statement. Cash and cash equivalents were $4,039 thousand at September 30, 2026, against $8,781 thousand at December 31, 2025, and the Company reports a further $5,039 thousand of restricted cash that sits in other assets. Net cash used in operating activities was $10.2 million for the nine months, which the filing describes as unchanged from the prior year period. Total liabilities rose to $9,386 thousand from $5,226 thousand, with notes payable now carried as Note A ($1,380 thousand current) and Note B ($4,884 thousand noncurrent). Total stockholders' equity fell to $2,622 thousand from $7,062 thousand. The September 29 exchange of $1.2 million of debt into Series B Preferred Stock is described by the Company as reducing the A-1 Note balance by approximately 43% and increasing stockholders' equity, and the balance sheet shows preferred stock of $3,384 thousand.

Strategically, the Company reports three changes: the October 21 agreement to transfer ThermoDox rights to VoxelDox in exchange for equity, milestone payments of up to $16.5 million and royalties, all conditional on VoxelDox raising $2.5 million; the September 10 CRADA under which NCI's CTEP will assume regulatory sponsorship of IMNN-001; and the October 27 Form S-1 filing for a proposed offering that has not yet become effective. Management frames the debt exchange and ThermoDox transaction as capital allocation steps that preserve financial flexibility. The filing does not state how long current cash and restricted cash will fund operations, and no going concern language appears in the text provided.

The investment case in this release rests on IMNN-001 and the OVATION 3 Phase 3 trial, which the Company says is expected to complete enrollment by the first quarter of 2029. The release describes Phase 2 OVATION 2 translational data, a DSMB recommendation to continue the MRD study without modification, and a poster at SITC 2026. These are development milestones and carry no reported financial value in this filing. The verdict is weak because the reported cash position, the equity decline and the pending equity offering weigh more heavily than the stable operating expense base in this quarter.

Management, verbatim

IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer.

Stacy R. Lindborg, Ph.D., President and Chief Executive Officer

Through our agreement to transition ThermoDox ® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.

Stacy R. Lindborg, Ph.D., President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year percentage changes for any line item (none printed)
  • Prior-year figure for nine-month net cash used in operating activities (the text says unchanged but does not print the number)
  • Q3 2026 and nine-month cash flow statement lines, other than net cash used in operating activities
  • Prior-quarter (Q2 2026) comparatives for any line item
  • Revenue, gross margin and cost of sales (no revenue line is reported)
  • Financial guidance or outlook for 2026 or later periods
  • Period-specific comparison of balance sheet items against September 30, 2025
  • Explanation of the change in other (expense) income
  • Size and terms of the proposed S-1 offering
  • Share count at period end and common shares outstanding (only weighted averages are printed)
  • The previous outlook covered enrollment timing for a study in the first half of 2029, which is a later period and not a reported metric, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readIMNN · Second quarter 2026 · ended June 30, 2026

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

→Mixed quarter

IMUNON reported continued clinical progress and enrollment exceeding its forecast in OVATION 3, while remaining pre-revenue in the filing, reporting net losses and higher first-half operating cash use.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net loss, three months ended June 30, 2026GAAP$2.8M––
Net loss per common share, basic and diluted, three months ended June 30, 2026GAAP$0.54 per share––
Research and development expenses, three months ended June 30, 2026GAAP$1.5M––
General and administrative expenses, three months ended June 30, 2026GAAP$1.3M––
Operating expenses, three months ended June 30, 2026GAAP$2.8M––
Loss from operations, three months ended June 30, 2026GAAP−$2.79M––
Other income(loss), net, three months ended June 30, 2026GAAP$ (22 )––
Weighted average shares outstanding, basic and diluted, three months ended June 30, 2026GAAP5,233––
Net loss, six months ended June 30, 2026GAAP$7.1M––
Net loss per common share, basic and diluted, six months ended June 30, 2026GAAP$1.38 per share––
Research and development expenses, six months ended June 30, 2026GAAP$3.8M––
General and administrative expenses, six months ended June 30, 2026GAAP$3.3M––
Operating expenses, six months ended June 30, 2026GAAP$7.1M––
Loss from operations, six months ended June 30, 2026GAAP−$7.10M––
Other income(loss), net, six months ended June 30, 2026GAAP$ 35––
Net cash used for operating activities, six months ended June 30, 2026GAAP$7M––

first half of 2029 outlook

  • NoteEnrollment in the Phase 3 OVATION 3 Study is expected to be completed by the first half of 2029.

What drove it

  • The Company said enrollment in the pivotal Phase 3 OVATION 3 study continues to exceed its planning assumptions.
  • Final Phase 2 OVATION 2 data showed a median 14.7-month increase in overall survival, with 45.1 vs. 30.4 months in the IMNN-001 treatment arm compared to SoC chemotherapy alone.
  • The independent Data Monitoring Committee recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial on June 23, 2026.
  • Preliminary Phase 2 MRD results showed a lower MRD-positive rate of 44% vs. 67%, ctDNA clearance of 87.5% vs. 62.5%, and NED of 100% vs. 56% for patients treated with IMNN-001 compared to control.
  • The Company attributed the increase in first-half operating cash use primarily to trial-related expenses associated with the OVATION 3 trial.
  • Research and development expenses increased during periods in which the Company initiated OVATION 3 enrollment during 2025 and closed out OVATION 2 during 2026.

Concerns

  • The filing reported net loss of $2.8 million for the second quarter of 2026 and $7.1 million for the first half of 2026.
  • Cash and cash equivalents were $6.9 million as of June 30, 2026.
  • Net cash used for operating activities was $7.0 million for the first half of 2026, compared with $5.8 million for the same period last year.
  • The June financing included secured promissory notes with principal amounts of $2.72 million and $5.0 million, bearing interest at 8% and 5%, respectively, per annum.
  • The filing provides preliminary MRD data and states that interim results are not necessarily indicative of final results.
  • The filing did not report revenue or financial guidance.

What to watch

  • OVATION 3 enrollment progress, which the Company said is exceeding its forecast, and expected completion by the first half of 2029.
  • Further data from the ongoing Phase 2 MRD clinical trial following the preliminary findings reported on July 21, 2026.
  • The Company’s R&D Day on September 23, 2026, in New York.
  • Clinical-trial expenses associated with OVATION 3 and their effect on operating cash use.
  • The maturity of the secured promissory notes 18 months after the issuance date.

Balance sheet and cash flow

  • As of June 30, 2026, cash and cash equivalents were $6.9 million.
  • Net cash used for operating activities was $7.0 million for the first half of 2026, compared with $5.8 million for the same period last year.
  • On June 4, 2026, the Company entered into definitive agreements with aggregate gross proceeds to the Company in the amount of $10 million.
  • The transaction includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured promissory notes in the principal amounts of $2.72 million and $5.0 million.
  • The promissory notes accumulate interest at a rate of 8% and 5%, respectively, per annum and mature 18 months after the issuance date. Interest will be partially offset with interest earned via bank deposit.

Analysis

IMUNON remains focused on clinical development rather than commercial operations. The filing did not report revenue or segments. Its operating update centered on IMNN-001, with the Company stating that OVATION 3 enrollment continues to exceed planning assumptions and that the trial moved from protocol submission to site activation in approximately 6 months and from protocol approval to first patient randomized in approximately 2 months.

The clinical evidence cited includes final Phase 2 OVATION 2 results showing a median 14.7-month increase in overall survival, with 45.1 vs. 30.4 months for the IMNN-001 treatment arm compared with SoC chemotherapy alone. The Company also reported preliminary MRD data, based on nine patients in each control and experimental arm reaching second-look laparoscopy, including a 44% vs. 67% MRD-positive rate, 87.5% vs. 62.5% ctDNA clearance, and 100% vs. 56% NED. The independent Data Monitoring Committee recommended continuation of OVATION 3.

Financially, second-quarter net loss was $2.8 million compared with $2.7 million, while operating expenses were $2.8 million in each period. Research and development expenses were $1.5 million compared with $1.2 million, and general and administrative expenses were $1.3 million compared with $1.5 million. For the first half, net loss was $7.1 million compared with $6.8 million, with research and development expense of $3.8 million compared with $3.4 million and general and administrative expense of $3.3 million compared with $3.5 million. The filing does not provide prior-quarter financial metrics, so quarter-over-quarter changes cannot be assessed from this document.

Cash and cash equivalents were $6.9 million as of June 30, 2026, and first-half net cash used for operating activities was $7.0 million compared with $5.8 million. Management attributed the increase to OVATION 3 trial-related expenses. The Company also entered financing agreements with aggregate gross proceeds of $10 million, including preferred stock and secured promissory notes. The stated development milestone is expected completion of OVATION 3 enrollment by the first half of 2029; the filing contains no revenue, expense, margin, tax-rate, or earnings guidance.

Management, verbatim

Enrollment in our pivotal Phase 3 OVATION 3 study continues to exceed our planning assumptions, reflecting the compelling survival data generated in OVATION 2, our highly favorable safety profile, and growing confidence among investigators in IMNN-001’s potential to improve outcomes for women with newly diagnosed advanced ovarian cancer.

Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON

We believe these findings provide further independent evidence of IMNN-001’s biological activity and reinforce the mechanism underlying the survival benefit observed in the OVATION 2 study, while we remain fully focused on our highest priority of efficiently advancing OVATION 3.

Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON

Not in the filing

stated, not guessed
  • Revenue
  • Segment revenue and segment comparisons
  • Gross profit and gross margin
  • Operating income
  • Non-GAAP measures, including non-GAAP operating income, net income, and EPS
  • Free cash flow
  • Quarterly operating cash flow
  • Debt balance as of June 30, 2026
  • Capital returns, including share repurchases and dividends
  • Prior-quarter financial metrics and quarter-over-quarter changes
  • Financial guidance for revenue, gross margin, operating expenses, tax rate, earnings, or cash flow
  • Prior outlook for guidance comparison
  • Tax expense or tax rate
  • Weighted average shares outstanding for the six months ended June 30, 2026

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about IMNN earnings dates

When is Imunon's next earnings date?
AlphAI has no date for IMNN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.